 |
23 Diseases |  |
176 Trials |
|
176 Trials |  |
4873 News |  |
| «12...4445464748495051525354...6162» |
- || Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Should $ABBV Venetoclax + Obinutuzumab be pulled from 1L setting for being too toxic? (Twitter) - Jul 4, 2019
- ||| In cll: Ibrutinib Acalabrutinib Venetoclax Obinutuzumab Pi3 inhibitors In nhl: Lenalidomide Polatuzumab Car-t We deride drug prices but it does foster profound innovation (Twitter) - Jul 4, 2019
- ||| Gazyva (obinutuzumab) / Biogen, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Monotherapy: Hi Jeff, Is there any data that shows that Obinutuzumab plus Ibrutinib results in improved outcomes compared to Ibrutinib monotherapy? Needing to decide on treatment very soon. thanks (Twitter) - Jul 3, 2019
- ||||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: GLOW: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov) - Jun 28, 2019
P3, N=211, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting
- | RG6123 / Roche
Trial completion date, Metastases: A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - Jun 27, 2019
P1, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial completion date: Jun 2021 --> Dec 2020
- | Gazyva (obinutuzumab) / Biogen, Roche
Clinical, Journal: Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia. (Pubmed Central) - Jun 26, 2019
Trial completion date: Jun 2021 --> Dec 2020 Obinutuzumab induces depletion of NK cells in CLL.
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche, Rituxan (rituximab) / Roche, Biogen
Journal: Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy. (Pubmed Central) - Jun 26, 2019
In our patients obinutuzumab was effective as first-line treatment of anti-MAG antibody polyneuropathy. CLL might have had a role in the response to therapy, but the associations might be considered in future trials.
- ||| idasanutlin (RG7388) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial termination, Combination therapy: A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants (clinicaltrials.gov) - Jun 24, 2019
P1/2, N=25, Terminated, Sponsor: Hoffmann-La Roche
CLL might have had a role in the response to therapy, but the associations might be considered in future trials. Active, not recruiting --> Terminated; Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.
- | Review, Journal: Novel agents for relapsed and refractory follicular lymphoma. (Pubmed Central) - Jun 22, 2019
Combination studies are currently underway with novel-novel combinations and with traditional chemotherapy regimens. This overview will discuss the results of several recent studies exploring activity of novel drugs in relapsed follicular lymphoma.
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal, IO biomarker: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. (Pubmed Central) - Jun 22, 2019
P3
Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.).
- ||| Gazyva (obinutuzumab) / Biogen, Roche
Thanks also to @Roche for the opportunity #gazyva (Twitter) - Jun 20, 2019
- |||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Clinical, P1 data, Combination therapy: CONGRESS #15ICML | @AnastasiosStat2 presents results of the SAKK 35/15 phase I trial of obinutuzumab in combination with #venetoclax in previously untreated FL pts. @EnteOspedaliero #lymsm #lymphoma #ICML19 (Twitter) - Jun 20, 2019
- |||| Revlimid (lenalidomide) / Celgene, Gazyva (obinutuzumab) / Biogen, Roche
Clinical: This supports our ongoing @SWOG S1608 trial in the POD 24 FL population, which includes lenalidomide and obinutuzumab as an arm. In collaboration with @ALLIANCE_org @eaonc (Twitter) - Jun 20, 2019
- ||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche, Tecentriq (atezolizumab) / Roche
Clinical, P2 data: Please stop by our poster (280) on the results of the safety run of our phase2 GATA study #venetoclax #obinutuzumab #atezolizumab from @LysaLymphoma for R/R #DLBCL #FL pts #15ICML in Lugano. See you today and tomorrow at 12:30 in front of the poster 😊 (Twitter) - Jun 20, 2019
- | Gazyva (obinutuzumab) / Biogen, Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme Therapeutics
Review, Journal: A tale of two antibodies: obinutuzumab versus rituximab. (Pubmed Central) - Jun 15, 2019
The benefit conferred by obinutuzumab over rituximab may be context-specific and vary based on histological subtype and immune integrity. This comprehensive review will explore the preclinical differences, investigate the proposed pathogenesis of rituximab resistance, compare the employed dosing strategies and interrogate available clinical results to help inform practice.
- | Rituxan (rituximab) / Roche, Biogen
Clinical, P3 data, Journal: Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. (Pubmed Central) - Jun 15, 2019
P3
PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed.
- | Gazyva (obinutuzumab) / Biogen, Roche
Journal: Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia. (Pubmed Central) - Jun 15, 2019
Additional supportive data are welcomed. No abstract available
- | Gazyva (obinutuzumab) / Biogen, Roche
Hints of promise with add on obinutuzumab!! NOBILITY trail. @RheumNow #EULAR2019 (Twitter) - Jun 14, 2019
- ||| Gazyva (obinutuzumab) / Biogen, Roche
Obinutuzumab: Press release on 2nd generation anti CD20 Using a multi target strategy #EULAR2019 (Twitter) - Jun 13, 2019
- | Anyara (naptumomab estafenatox) / NeoTX
New P1 trial, Combination therapy, Metastases: Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 12, 2019
P1b, N=45, Not yet recruiting, Sponsor: NeoTX Therapeutics Ltd.
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P1/2 trial: LEVERAGE: Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Na (clinicaltrials.gov) - Jun 10, 2019
P1/2, N=61, Not yet recruiting, Sponsor: Peter MacCallum Cancer Centre, Australia
- | Gazyva (obinutuzumab) / Biogen, Roche, Rituxan (rituximab) / Roche, Biogen
Clinical, Journal: Management of patients with follicular lymphoma treated first line with obinutuzumab. (Pubmed Central) - Jun 6, 2019
As median overall survival approaches 20 years or more, the long-term effects and sequencing of any strategy should be considered. Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma.
- ||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
Clinical: Hate chlorambucil as much as you want - hard to argue it hasn't been an acceptable standard in older patients who cannot tolerate BR/FCR. Combo therapy with obinutuzumab preserved it for a while, but I think it will soon cease to function as a comparitor arm following 2019/20 (Twitter) - Jun 6, 2019
- ||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
HEOR: This is a major advance. #Venetoclax very well tolerated. TLS risk partially mitigated by #obinutuzumab pretreatment. Most derive sustained benefit from fixed duration therapy. Cost effective around 1 year. We have no information on how well ibr works post ven - only caution (Twitter) - Jun 4, 2019
- | Gazyva (obinutuzumab) / Biogen, Roche
What are you going to use? Ibr +/-Gazyva or Ven+Gazyva? (Twitter) - Jun 4, 2019
- ||| Gazyva (obinutuzumab) / Biogen, Roche, Calquence (acalabrutinib) / AstraZeneca
#ASCO19 Woyach: 3yr followup of Acalabrutinib+Obinutuzumab in 1st line (n=19) and salvage (26), 78% remain on treatment (Twitter) - Jun 4, 2019
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial suspension: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 3, 2019
P1, N=60, Suspended, Sponsor: Beth Christian
Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma. Recruiting --> Suspended
- ||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
We may already have the drugs to confer really long PFS in #CLL with low toxicity. Inclusion of #venetoclax in regimen appears important. Question remains which are the best partners? #ibrutinib and/or #obinutuzumab? #lymphoma https://t.co/qsQKasjfDo (Twitter) - Jun 1, 2019
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Clinical: Upfront venetoclax / obinutuzumab data coming on Tuesday at #ASCO19. Abstract looks promising; deep remissions, impressive MRD negativity rates. A fixed-duration non-chemotherapeutic option in #CLL is intriguing: https://t.co/2CbWFaDkd5 https://t.co/1ttHN9c1RV (Twitter) - Jun 1, 2019
- ||| Gazyva (obinutuzumab) / Biogen, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Dramatic changes in #CLL lately. Ibrutinib is standard upfront option now, and we're seeing novel non-chemo combos tested. Recent @NEJM study shows ibru/ven combo = 88% CR/CRi rate, 61% MRD neg! Upfront ven/obinutuzumab data coming at #ASCO19 https://t.co/NENDxEXLei #leusm (Twitter) - Jun 1, 2019
- | Trial suspension, FDG PET, Metastases: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (clinicaltrials.gov) - May 30, 2019
P1, N=26, Suspended, Sponsor: Mayo Clinic
Recruiting --> Suspended Recruiting --> Suspended
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
Journal: Frontline treatment of chronic lymphocytic leukemia with obinutuzumab and chlorambucil: how does it work in "real‑life"? (Pubmed Central) - May 29, 2019
Recruiting --> Suspended No abstract available
- |||| Gazyva (obinutuzumab) / Biogen, Roche, Calquence (acalabrutinib) / AstraZeneca
Clinical: Woyach et al -Acalabrutinib+Obinutuzumab in TN and R/R #CLL. - 19 TN and 26 R/R pts - Common G3/4 AEs low ANC (24%), syncope (11%), low plts (9%), (4%) G3 bleeding, 2% G3 AF. - High and durable ORR - 36m PFS: 94% in TN and 73% in RR pts #Blooducation #CLL #ASCO2019 (Twitter) - May 29, 2019
- || Trial primary completion date, Combination therapy: GO29833: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - May 28, 2019
P1, N=134, Recruiting, Sponsor: Hoffmann-La Roche
No abstract available Trial primary completion date: Dec 2021 --> Jul 2019
- || Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: GO29834: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - May 28, 2019
P1, N=128, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2021 --> Jul 2019 Trial primary completion date: Feb 2022 --> Aug 2019
- || Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
@EmboMolMed @IREISGufficiale @The_OIRO didn’t they jack up the price when gazyva chlorambucil data came out? (Twitter) - May 24, 2019
- | Gazyva (obinutuzumab) / Biogen, Roche
Clinical, Journal: Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. (Pubmed Central) - May 24, 2019
P3
Frontline G-B appears to have manageable toxicity with clinical activity in CLL. Careful TLS risk assessment, pretreatment and monitoring is required.
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Clinical, FDA event: With the new @US_FDA approval of venetoclax plus obinutuzumab, our @NitinJainMD says “the big question in the field” is choosing which frontline treatment will be best for chronic lymphocytic #leukemia patients: https://t.co/Go3vczNgJt @medpagetoday #leusm #endcancer (Twitter) - May 21, 2019
- || Calquence (acalabrutinib) / AstraZeneca
Enrollment change, Metastases: A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies (clinicaltrials.gov) - May 21, 2019
P1, N=34, Recruiting, Sponsor: AstraZeneca
Careful TLS risk assessment, pretreatment and monitoring is required. N=25 --> 34
- ||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Dr. Brian Koffman comments on the importance of the approval of Venetoclax + Obinutuzumab in the frontline setting for CLL/SLL: https://t.co/FXZRgtQgS9 #CLL #SLL #LetsCureThis #Venetoclax (Twitter) - May 20, 2019
- | Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open, Trial primary completion date: OLYMP-1: Obinutuzumab in Marginal Zone Lymphoma (clinicaltrials.gov) - May 20, 2019
P2, N=56, Recruiting, Sponsor: Christian Buske
N=25 --> 34 Not yet recruiting --> Recruiting | Trial primary completion date: May 2019 --> Oct 2019
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Clinical, FDA event: May stay in second line after CLL14 (venetoclax-obinutuzumab) is presented at ASCO. Already approved by FDA and offers the appeal of fixed duration treatment @mshadman (Twitter) - May 19, 2019
- ||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
HEOR, Monotherapy: Cost effective breakpoint for gazyva with venetoclax compared to ibrutinib monotherapy probably just short of two years I imagine? From there out combo therapy gets less expensive (Twitter) - May 19, 2019
- ||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Clinical, P3 data, Monotherapy: At least in this case the control wasn’t chlorambucil monotherapy; that would have been unconscionable at trial start in ~2014. Similar design to the ILLUMINATE Phase 3 (ibrutinib + obinutuzumab vs chlorambucil + obinutuzumab) - that one reported out a few months ago. (Twitter) - May 16, 2019
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
FDA event: FDA Approves Venetoclax–Obinutuzumab Combo for Untreated CLL or SLL | Oncology Newswatch https://t.co/M7VJJYfiNO (Twitter) - May 16, 2019
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Clinical: #ASCO19 $RHHBY - Venclextax+Gazyva in Ph3 CLL14, 1L in CLL pts n=432 (ITT) Follow-up: 29m (Twitter) - May 15, 2019
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
FDA event: Venetoclax/Obinutuzumab Combo Approved by FDA for Frontline CLL https://t.co/WtzxqmAxYR via @TargetedOnc (Twitter) - May 15, 2019
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
Clinical, FDA event: Venetoclax/Obinutuzumab Combo Approved by FDA for Frontline CLL https://t.co/6rH2MP4Ly1 via @TargetedOnc. A great advance for patients with CLL! (Twitter) - May 15, 2019
- |||| Trial completion, Combination therapy: ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - May 15, 2019
P2, N=230, Completed, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: May 2019 --> Oct 2019 Active, not recruiting --> Completed